Progress in new-type vaccines against classical swine fever.
- Author:
Chunhua WANG
1
;
Yuan SUN
;
Huaji QIU
Author Information
1. State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150001, Heilongjiang, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Classical Swine Fever;
prevention & control;
Classical swine fever virus;
Swine;
Vaccination;
veterinary;
Vaccines, Attenuated;
immunology;
Vaccines, DNA;
immunology;
Vaccines, Subunit;
immunology;
Viral Vaccines;
immunology
- From:
Chinese Journal of Biotechnology
2013;29(7):880-890
- CountryChina
- Language:Chinese
-
Abstract:
Classical swine fever (CSF), an acute and highly contagious disease of swine, is caused by classical swine fever virus. CSF is one of the most devastating diseases to the pig industry worldwide and results in serious economic losses. Currently prophylactic vaccination is still an important strategy for the control of CSF. Live attenuated vaccines (such as C-strain) are safe and effective. However, there are significant changes in the clinical features of CSF, displaying concurrent typical and atypical CSF, and simultaneous inapparent and persistent infections. Immunization failure has been reported frequently and it is difficult to distinguish between wild-type infected and vaccinated animals (DIVA). So there is an urgent need to develop more effective and safer DIVA or marker vaccines for the control of CSF. In this review, some of the most recent advances in new-type vaccines against CSF, including DNA vaccines, live virus-vectored vaccines, protein or peptide-based vaccines, gene-deleted vaccines and chimeric pestivirus-based vaccines, are reviewed and discussed.
